Sarasota, Florida | December 30, 2025 — Silo Pharma, Inc. has taken a key step toward early-stage clinical development by executing a Letter of Intent (LOI) with Allucent, a global clinical research organization, to support Phase 1 clinical studies of SPC-15, an investigational intranasal therapy for stress-induced psychiatric conditions. The planned Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) studies are designed to generate foundational safety and pharmacokinetic data, marking an important clinical inflection point for the company’s central nervous system (CNS) pipeline.
Science Significance
From a scientific standpoint, SPC-15 represents a novel intranasal formulation targeting the serotonin 5-HT4 receptor, an approach intended to enable rapid central nervous system delivery while potentially reducing systemic exposure. The planned Phase 1 SAD and MAD studies will evaluate dose-dependent safety, tolerability, and pharmacokinetics in healthy subjects, which are critical parameters for first-in-human development. By combining a soft mist nasal spray delivery system with a well-characterized pharmacologic target, the program reflects growing scientific interest in non-oral, CNS-directed drug delivery technologies designed to address unmet needs in psychiatric disorders such as post-traumatic stress disorder (PTSD) and anxiety.
Regulatory Significance
The announcement is highly relevant from a cGxP and regulatory perspective, as Phase 1 clinical trials are governed by Good Clinical Practice (GCP) standards and form the foundation for subsequent regulatory interactions. The scope of services outlined under the LOI—including clinical operations, pharmacovigilance, data management, biostatistics, and medical writing—demonstrates a structured approach to regulatory-compliant trial execution and reporting. Additionally, SPC-15 is being developed with the intention of pursuing an accelerated approval pathway under Section 505(b)(2), highlighting strategic regulatory planning aimed at leveraging existing scientific knowledge while meeting U.S. Food and Drug Administration requirements.
Business Significance
Advertisement
From a business perspective, the collaboration underscores how emerging biopharmaceutical companies leverage CRO partnerships to efficiently advance clinical pipelines. By engaging Allucent at this stage, Silo Pharma is positioning itself to optimize resource allocation, manage development risk, and accelerate timelines without building extensive internal clinical infrastructure. Successful execution of the Phase 1 program would not only de-risk SPC-15 scientifically but also enhance the overall value of Silo Pharma’s CNS-focused portfolio, supporting long-term growth and potential strategic opportunities within the competitive neuropsychiatric market.
Patients’ Significance
For patients, particularly those affected by PTSD and anxiety disorders, the advancement of SPC-15 into Phase 1 represents progress toward new therapeutic options in areas where existing treatments may be inadequate or poorly tolerated. Intranasal delivery has the potential to offer faster onset of action and improved adherence, factors that are especially important in acute or stress-related psychiatric conditions. While early-stage clinical trials do not provide direct patient benefit, they are an essential step toward expanding future treatment choices and improving outcomes for individuals living with chronic mental health conditions.
Policy Significance
At the policy level, the development of SPC-15 reflects broader trends in mental health innovation and regulatory support for CNS drug development. Increasing recognition of the societal and economic burden of psychiatric disorders has driven interest in novel mechanisms of action, alternative delivery routes, and streamlined regulatory pathways. Programs like SPC-15 align with policy objectives aimed at encouraging innovation while maintaining rigorous safety and quality standards, reinforcing the importance of early-phase clinical research within regulated frameworks.
In summary, Silo Pharma’s LOI with Allucent marks a strategically significant milestone in the clinical advancement of SPC-15, bringing together scientific innovation, regulatory discipline, and operational expertise. As the company prepares to initiate Phase 1 SAD and MAD studies, the program exemplifies how biopharmaceutical development progresses from preclinical promise to regulated clinical evaluation. For the cGxP.wire audience, this development highlights the continued importance of GCP-compliant early-stage trials, CRO partnerships, and regulatory foresight in shaping the future of CNS therapeutics.
Source: Silo Pharma, Inc press release
